Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / MiNK Therapeutics Doses First Patient
Tech clinical trial

MiNK Therapeutics Doses First Patient

Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The dosing of the first patient in the Phase 2 trial for agenT-797 by MiNK Therapeutics could significantly impact the biotechnology and pharmaceutical markets. A successful outcome could lead to a new mortality-reducing therapy for acute lung injury, potentially boosting MiNK Therapeutics' stock and attracting investment in similar immune therapies.

Biotechnology Pharmaceuticals Healthcare
Event Summary

MiNK Therapeutics announced the dosing of the first patient in its randomized Phase 2 clinical trial (C-1300-02) evaluating agenT-797 for severe acute lung injury and critical illness. The trial, conducted in collaboration with First Lviv Territorial Medical Union and UNBROKEN Ukraine in Lviv, Ukraine, received rapid approval from the Malaysia — Ministry of Health (Malaysia). This milestone marks a significant advancement in developing a first-in-class immune therapy for conditions with high mortality and no approved treatments. Preliminary data from the trial are expected in the second half of 2026. The study aims to assess clinically meaningful ICU outcomes, including survival and ventilator-free days, and is supported by an active U.S. IND with U.S. site expansion underway.

Key Actions
100 MiNK Therapeutics initiated Phase 2 trial
90 MiNK Therapeutics initiated study First Lviv Territorial Medical Union
80 Malaysia — Ministry of Health (Malaysia) approved clinical trial MiNK Therapeutics
Entities Involved
stock
MiNK Therapeutics
MiNK Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial for agenT-797, a significant step in developing a new therapy for acute lung injury and critical illness. This advancement could positively impact its stock price and market position.
Importance 100 Sentiment 70
oth
First Lviv Territorial Medical Union
First Lviv Territorial Medical Union is a key site for the clinical trial, demonstrating its capability to conduct advanced medical research in a high-acuity environment.
Importance 80 Sentiment 50
per
Jennifer Buell
As President and CEO of MiNK Therapeutics, Jennifer Buell's statements highlight the importance of this clinical trial for critical illness, reinforcing the company's commitment to addressing unmet medical needs.
Importance 70 Sentiment 60
cnt
Ukraine
Ukraine is the location where the first patient was dosed, with the Malaysia — Ministry of Health (Malaysia) providing approval for the trial. This highlights Ukraine's role in global medical research.
Importance 70 Sentiment 40
per
Terese Hammond
As Head of R&D at MiNK Therapeutics, Terese Hammond provided insights into the trial's design and its potential to address immune dysfunction in critically ill patients.
Importance 60 Sentiment 60
govactor
Malaysia — Ministry of Health (Malaysia)
The Malaysia — Ministry of Health (Malaysia) granted approval for the clinical trial, enabling the rapid initiation of treatment for patients with acute lung injury.
Importance 60 Sentiment 50
ngo
UNBROKEN Ukraine
UNBROKEN Ukraine collaborated with First Lviv Territorial Medical Union in the initiation of the clinical trial, supporting the treatment and recovery of individuals affected by war.
Importance 50 Sentiment 50
per
Khrystyna Orlynska
As Principal Investigator and Head of the Department of Anesthesiology and Intensive Care at First Lviv Territorial Medical Union, Dr. Khrystyna Orlynska emphasized the importance of the study for critically ill patients in Ukraine.
Importance 50 Sentiment 50
per
Demian Kalysh
As Sub-Investigator in Anesthesiology and Pulmonary Critical Care, Dr. Demian Kalysh highlighted the scientific and patient-centric significance of evaluating an off-the-shelf immune restorative therapy.
Importance 50 Sentiment 50
cnt
United States
The clinical trial is supported by an active U.S. IND, with U.S. site expansion underway, indicating future regulatory pathways in the United States.
Importance 20 Sentiment 0
loc
Europe
Clinical care standards in Ukraine are aligned with modern Western intensive care practices, supporting data generation for future regulatory pathways in Europe.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.